LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 GuidanceBusiness Wire • 02/25/25
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant DepressionBusiness Wire • 12/18/24
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual MeetingBusiness Wire • 12/05/24
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should KnowZacks Investment Research • 11/28/24
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary EndpointZacks Investment Research • 11/18/24
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare ConferencesBusiness Wire • 11/14/24
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy EndpointsBusiness Wire • 11/11/24
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 11/07/24
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%Zacks Investment Research • 11/07/24